SC
ASMB icon

Stempoint Capital’s Assembly Biosciences ASMB Stock Holding History

Stempoint Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.68M Sell
170,378
-15,057
-8% -$410K 0.81% 38
2026
Q1 		$5.15M Buy
185,435
+28,707
+18% +$819K 0.99% 33
2025
Q4 		$5.33M Buy
156,728
+90,598
+137% +$2.92M 0.91% 36
2025
Q3 		$1.69M Buy
+66,130
New +$1.45M 0.34% 53

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Stempoint Capital's ASMB Position: Q2 2026 in Review

Stempoint Capital reduced its Assembly Biosciences (ASMB) stake by 8.1% in Q2 2026, selling an estimated $410K and leaving 170,378 shares worth $4.68M. The position accounts for 0.81% of the portfolio, ranked #38.

Stempoint Capital first reported a position in ASMB in Q3 2025 and has held it in 4 quarters since. The position peaked at $5.33M in Q4 2025. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Stempoint Capital held 170,378 shares of Assembly Biosciences worth $4.68M as of Q2 2026.
  • Stempoint Capital sold 15,057 Assembly Biosciences shares in Q2 2026, an estimated $410K.
  • Assembly Biosciences made up 0.81% of Stempoint Capital's portfolio in Q2 2026, its #38 holding.
  • Stempoint Capital first reported a position in Assembly Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Stempoint Capital's Assembly Biosciences position peaked at $5.33M in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.